CEBPZ and acute myeloid leukemia: Although CBF AML has a relatively favourable prognosis compared with other non-M3 AML subtypes, there are yet heterogeneities across different CBF subtypes, making it possible to further improve the therapeutic effects in t(8; 21) AML patients.